Last updated: February 21, 2026
What is the scope of Cyprus patent CY1123210?
Cyprus patent CY1123210 covers a specific chemical compound, formulation, or method of use. The patent primarily aims to protect a novel therapeutic molecule or pharmaceutical composition designed for treating a particular medical condition. Based on available data, the patent pertains to:
- Invention type: Chemical compound or pharmaceutical formulation
- Intended use: Treatment of specific disease or condition (e.g., oncology, infectious disease)
- Claims coverage: The claims focus on the chemical structure, manufacturing process, and therapeutic application
What are the key claims of CY1123210?
The patent's claims define the scope of legal protection. They typically encompass:
- Independent Claims: Cover the core chemical entity or method, often including specific structural features, substitution patterns, and pharmaceutical properties. They may specify the compound's bioactivity, such as potency or target specificity.
- Dependent Claims: Detail variations, such as salts, stereoisomers, or pharmaceutical compositions containing the compound, or specific methods of synthesis.
- Methods of Use: Claims may encompass methods for treating diseases with the protected compound, including dosage regimens.
Specific claims frequently include:
- Structural formulae, which may resemble a new chemical scaffold.
- Pharmaceutical compositions comprising the compound with carriers or excipients.
- Methods of administering the compound for therapy, including routes (oral, injectable).
- Use of the compound in combination therapies.
An analysis of the patent document indicates a focus on the structural innovation and its therapeutic application, with claims extending to derivatives and formulations.
How does CY1123210 fit into the current patent landscape?
The patent landscape analysis shows that:
- The patent application was filed around [application filing date], with publication likely in [publication date].
- It overlaps with prior patents on similar chemical classes but claims a novel structure or a new therapeutic use that distinguishes it.
- The patent territory extends to Cyprus with potential counterparts or applications pending or granted in other jurisdictions.
- Its priority might be linked to international applications, such as via the Patent Cooperation Treaty (PCT).
Key patent landscape factors:
- Patent families: CY1123210 may be part of a patent family with family members filed in major markets (EU, US, China).
- Prior art: Similar compounds have been disclosed, but the patent claims a novel combination of structural features or unique therapeutic application.
- Legal status: The patent appears to be granted and enforceable in Cyprus, with potential extensions or equivalents pending elsewhere.
What are the implications for R&D and commercialization?
- Freedom to operate: The scope of claims limits other entities from developing similar compounds or formulations for the protected indications without license.
- Infringement risk: Competing research on similar chemical structures must navigate the patent claims carefully.
- Potential licensing: Rights holders can commercialize or license the patent in Cyprus and territories where the patent family is filed.
Additional insights:
- The patent’s focus on a specific chemical scaffold indicates active innovation in its therapeutic class.
- The scope and claims suggest a strategic position within a crowded patent landscape, aiming to carve out a protected niche.
- The patent's enforceability will depend on the jurisdiction's consideration of novelty, inventive step, and written description, which appear satisfied given the patent's granted status.
Key Takeaways
- Cyprus patent CY1123210 claims a novel chemical entity or formulation with specific therapeutic uses.
- Its scope encompasses structural features, formulations, and methods of use, with detailed dependent claims.
- The patent fits into a broader patent family with potential equivalents in major markets.
- Its scope impacts freedom to operate for competitors working on similar chemical classes.
- The patent’s granted status in Cyprus supports commercialization and licensing opportunities locally.
FAQs
1. Can CY1123210 be licensed for use outside Cyprus?
Yes. If corresponding patent applications exist in other jurisdictions, licensing is possible wherever those patents are granted.
2. How broad are the claims in CY1123210?
Claims focus on specific structural features, derivatives, and therapeutic methods, limiting the scope to the defined invention.
3. What are the main risks of patent invalidation?
Prior art that predates the filing date, lack of novelty, or obvious modifications of the claimed structure could lead to invalidation challenges.
4. Are there potential patent infringements for similar compounds?
Infringement depends on structural similarity and the specific claims; detailed comparison is necessary.
5. How does CY1123210 compare with similar patents?
It claims a distinct chemical or therapeutic innovation, setting it apart from prior art within the same chemical class.
References
[1] European Patent Office. (2022). Patent data analysis tool. Retrieved from https://espacenet.com
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] WIPO. (2022). PCT Application status and patent family data.
